Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · April 09, 2020

Gemcitabine + Pazopanib vs Gemcitabine Alone for Persistent or Recurrent Epithelial Ovarian Carcinoma

Gynecologic Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Gynecologic Oncology
A Randomized Phase II Evaluation of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Persistent or Recurrent Epithelial Ovarian Carcinoma
Gynecol. Oncol 2020 Apr 01;[EPub Ahead of Print], LR Duska, GR Petroni, N Varhegyi, J Brown, D Jelovac, KN Moore, WP McGuire, C Darus, LM Barroilhet, AA Secord

Further Reading